• Users Online: 100
  • Print this page
  • Email this page
Year : 2019  |  Volume : 3  |  Issue : 3  |  Page : 687-692

Metabolic changes after laparoscopic sleeve gastrectomy

Department of General Surgery, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

Correspondence Address:
BSc Samar R Elsayed Abo Elenin
Department of General Surgery, Faculty of Medicine for Girls, Al-Azhar University, Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sjamf.sjamf_84_19

Get Permissions

Introduction Obesity is a major cause of premature death, and its prevalence is increasing worldwide. Obesity is a major risk factor for the development of insulin-resistance type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia. Aim The aim of this study was to evaluate the effects of laparoscopic sleeve gastrectomy (LSG) on metabolic diseases such as diabetes mellitus, hypertension, and dyslipidemia. Patients and methods This is a prospective and retrospective study that included 30 patients. All patients underwent LSG as a primary one-stage bariatric procedure in Al Zahraa University Hospital during the period from 2018 till 2019. Preoperative evaluation followed the same standard protocol and included a thorough history, complete endocrinal workup, and counseling by a dietician. All patients underwent upper abdominal ultrasonography, to especially exclude gallstones. All comorbidities that increase perioperative risk were controlled before surgery as far as possible. Results One of the main purposes of this study was to investigate further the effect of LSG on T2DM, hypertension, and hyperlipidemia. Our study shows that LSG resolved or improved lipid profile in most patients. After 12 months from surgery, significant changes in lipid profile included increased level of high-density lipoprotein and decreased level of cholesterol, triglycerides, and low-density lipoprotein level, and also improvement of T2DM and hypertension. Conclusion According to our results, we have shown that at 12 months after surgery, SG is effective in inducing remission of obesity-associated metabolic comorbidities, such as T2DM, hypertension, and hyperlipidemia.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal